Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab Phase 2 in RRMS
NCT00882999Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2009
- Primary completion
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of tabalumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Eli Lilly and Company. Started Apr 2009; status: completed.
02
Drugs
tabalumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00882999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882999.